60 Degrees Pharma Files 8-K on Common Stock & Warrants

TL;DR

**60 Degrees Pharma just confirmed its stock and warrants are still registered and tradable.**

AI Summary

60 DEGREES PHARMACEUTICALS, INC. filed an 8-K on January 16, 2024, reporting an event on January 10, 2024, related to its Common Stock, par value $0.0001 per share, and Warrants. This filing indicates that the company is maintaining its registration for these securities on an exchange, which is a standard procedural update. For investors, this means the company continues to meet its listing requirements, ensuring the stock and warrants remain tradable.

Why It Matters

This filing confirms the continued registration of 60 DEGREES PHARMACEUTICALS, INC.'s common stock and warrants, which is crucial for their liquidity and tradability on public exchanges.

Risk Assessment

Risk Level: low — This 8-K is a routine procedural filing with no immediate financial or operational impact, indicating low risk.

Analyst Insight

Investors should view this as a routine compliance update, confirming the continued tradability of the company's securities. No immediate action is required based on this specific filing, but it's a good reminder to stay informed on all company disclosures.

Key Numbers

• $0.0001 — Par Value per Share (The par value of 60 DEGREES PHARMACEUTICALS, INC.'s Common Stock.)

Key Players & Entities

• 60 DEGREES PHARMACEUTICALS, INC. (company) — registrant
• $0.0001 (dollar_amount) — par value per share of Common Stock
• January 10, 2024 (date) — date of earliest event reported
• January 16, 2024 (date) — filing date of the 8-K

FAQ

Key Financial Figures

• $0.0001 — h registered Common Stock, par value $0.0001 per share SXTP The Nasdaq Stock Mar
• $1.00 — intained a minimum closing bid price of $1.00 per share required for continued listin

Filing Documents

• ea191500-8k_60degrees.htm (8-K) — 28KB
• 0001213900-24-003691.txt ( ) — 240KB
• sxtp-20240110.xsd (EX-101.SCH) — 4KB
• sxtp-20240110_def.xml (EX-101.DEF) — 26KB
• sxtp-20240110_lab.xml (EX-101.LAB) — 36KB
• sxtp-20240110_pre.xml (EX-101.PRE) — 25KB
• ea191500-8k_60degrees_htm.xml (XML) — 5KB

01 Other Events

Item 8.01 Other Events. As previously reported, on November 2, 2023, 60 Degrees Pharmaceuticals, Inc. (the "Company") received a letter from the Nasdaq Listing Qualifications Staff of The Nasdaq Stock Market LLC ("Nasdaq") therein stating that for the 30 consecutive business day period between September 19, 2023 through November 1, 2023, the common stock of the Company had not maintained a minimum closing bid price of $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the "Bid Price Rule"). On January 10, 2024, the Company received a letter from the Listing Qualifications Staff of Nasdaq informing the Company that for the 10 consecutive business day period between December 26, 2023 through January 9, 2024, the closing bid price of the Company's common stock has been at $1.00 per share or greater. Accordingly, the Company has regained compliance with Listing Rule 5550(a)(2) and this matter is closed. 1

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. 60 DEGREES PHARMACEUTICALS, INC. Date: January 16, 2024 By: /s/ Geoffrey Dow Name: Geoffrey Dow Title: Chief Executive Officer and President 2

View Full Filing

View this 8-K filing on SEC EDGAR